VivoSim Labs, Inc. (VIVS) - Total Assets
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) holds total assets worth $6.96 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VIVS debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
VivoSim Labs, Inc. - Total Assets Trend (2011–2025)
This chart illustrates how VivoSim Labs, Inc.'s total assets have evolved over time, based on quarterly financial data. See shareholders equity of VivoSim Labs, Inc. for net asset value and shareholders' equity analysis.
VivoSim Labs, Inc. - Asset Composition Analysis
Current Asset Composition (March 2025)
VivoSim Labs, Inc.'s total assets of $6.96 Million consist of 82.8% current assets and 17.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.2% |
| Accounts Receivable | $30.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how VivoSim Labs, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VIVS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VivoSim Labs, Inc.'s current assets represent 82.8% of total assets in 2025, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 77.2% of total assets in 2025, up from 41.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
VivoSim Labs, Inc. Competitors by Total Assets
Key competitors of VivoSim Labs, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
VivoSim Labs, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.44 | 0.72 | 53.26 |
| Quick Ratio | 2.44 | 0.72 | 53.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.57 Million | $-837.00K | $37.68 Million |
VivoSim Labs, Inc. - Advanced Valuation Insights
This section examines the relationship between VivoSim Labs, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 130.7% |
| Total Assets | $14.65 Million |
| Market Capitalization | $997.45K USD |
Valuation Analysis
Below Book Valuation: The market values VivoSim Labs, Inc.'s assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: VivoSim Labs, Inc.'s assets grew by 130.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for VivoSim Labs, Inc. (2011–2025)
The table below shows the annual total assets of VivoSim Labs, Inc. from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $14.65 Million | +130.74% |
| 2024-03-31 | $6.35 Million | -68.74% |
| 2023-03-31 | $20.31 Million | -38.99% |
| 2022-03-31 | $33.30 Million | -16.59% |
| 2021-03-31 | $39.92 Million | +40.35% |
| 2020-03-31 | $28.44 Million | -29.99% |
| 2019-03-31 | $40.62 Million | -18.47% |
| 2018-03-31 | $49.83 Million | -27.97% |
| 2017-03-31 | $69.18 Million | +2.37% |
| 2016-03-31 | $67.58 Million | +26.34% |
| 2015-03-31 | $53.49 Million | +6.58% |
| 2014-03-31 | $50.19 Million | +199.64% |
| 2013-03-31 | $16.75 Million | +391689.47% |
| 2011-03-31 | $4.28K | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucida… Read more